Latest Innovation News

Amaero has inked a five-year exclusive supply agreement with Velo3D, valued at approximately A$35 million, to provide critical titanium and refractory alloy powders for advanced metal 3D printing. This partnership underscores a strategic push to bolster U.S. domestic manufacturing capabilities in aerospace and defense sectors.

WA Kaolin Limited has ramped up production with new classifiers, achieving record sales and securing a $7 million capital raise, while expanding its footprint in the Chinese market.

Resonance Health reports record $14.9M cash receipts over 12 months and completes cost-cutting measures while advancing two major pharma clinical trials on schedule.

Harmoney Corp upgrades its FY25 cash NPAT guidance to $5.5 million, driven by strong loan book growth and improved margins, while announcing a strategic 5% on-market share buy-back.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

GreenHy2 Limited reports a strategic push in Europe with new contracts for its advanced supercapacitor and hydrogen storage technologies, alongside a cash position of $814K and four quarters of funding runway.

Vital Metals is nearing completion of a pivotal Scoping Study for its Tardiff deposit in Canada, while spearheading a new Canadian rare earths consortium and securing fresh funding to support its development ambitions.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Strategic Energy Resources advances its copper-gold and polymetallic exploration with refined drill targets at Isa North, promising anomalies at South Cobar, and a major new gold project granted in Queensland, while managing funding and asset divestment.

Nuchev Limited reported a remarkable 215% increase in quarterly revenue, driven by the strategic launch of Oli6® in Vietnam and the acquisition of bWellness, signaling robust expansion across key Asia-Pacific markets.

Immutep Limited has dosed the first patient in its pivotal Phase III lung cancer trial and completed enrolments in multiple studies, supported by a robust cash position expected to fund operations through 2026.

RMA Global Limited reported a robust Q3 FY25, achieving a 21% revenue increase to $5.5 million and marking its third consecutive quarter of positive operating cash flow, driven by US market expansion and the strategic acquisition of Curated Social.